"More than 380 clinical trials and tens of thousands of participants were disrupted by cuts to grant funding from the National Institutes of Health this year, according to a research analysis published Monday by JAMA Internal Medicine."
"The authors examined 11,008 clinical trials funded between Feb. 28 and Aug. 15 by active NIH grants and found that 383 of them-or 3.5 percent-had lost grant funding by Aug. 15."
"Because trials require sustained financial support to ensure operations and participant safety, unanticipated funding disruptions raise concerns about avoidable waste, data quality, and compromised ethical obligations to participants,"
11,008 clinical trials were funded between Feb. 28 and Aug. 15 by active NIH grants; 383 trials (3.5%) lost grant funding by Aug. 15. Of the affected trials, about 36% were completed, 34% were recruiting, 13.7% were not yet recruiting, and 11% were active but no longer recruiting; the latter 43 trials enrolled a combined 74,311 participants. Affected trials most often focused on infectious diseases (14.4%), respiratory diseases (5.8%), and cardiovascular diseases (5.0%). More than 4,400 NIH-funded trials focused on cancer, with 118 (2.7%) having grants canceled. Trials in the Northeast and outside the U.S. were disproportionately affected, raising concerns about waste, data quality, and ethical obligations to participants.
Read at Inside Higher Ed | Higher Education News, Events and Jobs
Unable to calculate read time
Collection
[
|
...
]